Swiss National Bank Has $2.28 Million Position in CG Oncology, Inc. (NASDAQ:CGON)

Swiss National Bank lifted its stake in CG Oncology, Inc. (NASDAQ:CGON) by 144.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 79,600 shares of the company’s stock after buying an additional 47,000 shares during the period. Swiss National Bank owned about 0.10% of CG Oncology worth $2,283,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. State Street Corp lifted its position in shares of CG Oncology by 73.0% in the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company’s stock worth $64,166,000 after acquiring an additional 717,722 shares during the period. Janus Henderson Group PLC raised its stake in shares of CG Oncology by 7.0% in the third quarter. Janus Henderson Group PLC now owns 1,526,534 shares of the company’s stock valued at $57,596,000 after purchasing an additional 99,517 shares in the last quarter. Franklin Resources Inc. lifted its position in CG Oncology by 8.9% in the third quarter. Franklin Resources Inc. now owns 1,230,193 shares of the company’s stock worth $46,157,000 after purchasing an additional 100,106 shares during the period. Geode Capital Management LLC boosted its stake in CG Oncology by 96.2% during the third quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company’s stock worth $40,701,000 after buying an additional 528,749 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in CG Oncology by 575.7% during the third quarter. Point72 Asset Management L.P. now owns 746,063 shares of the company’s stock worth $28,149,000 after buying an additional 635,653 shares in the last quarter. 26.56% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on CGON shares. Morgan Stanley reaffirmed an “overweight” rating and set a $55.00 price objective on shares of CG Oncology in a report on Friday, March 7th. Royal Bank of Canada restated an “outperform” rating and set a $66.00 price target on shares of CG Oncology in a research note on Friday, December 6th. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Tuesday. Finally, TD Cowen started coverage on CG Oncology in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $63.88.

CG Oncology Price Performance

CG Oncology stock opened at $26.94 on Friday. The business’s fifty day moving average is $27.96 and its two-hundred day moving average is $31.94. CG Oncology, Inc. has a 52 week low of $23.91 and a 52 week high of $46.99.

Insider Activity at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.